Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial.
about
Erythropoietin Pathway: A Potential Target for the Treatment of DepressionCognitive remission: a novel objective for the treatment of major depression?Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive ReviewA neurocognitive model for understanding treatment action in depressionThe effect of recombinant erythropoietin on plasma brain derived neurotrophic factor levels in patients with affective disorders: a randomised controlled study.Imaging and serum biomarkers reflecting the functional efficacy of extended erythropoietin treatment in rats following infantile traumatic brain injury.Erythropoietin: emerging role of erythropoietin in neonatal neuroprotection.Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder.The prevalence, measurement, and treatment of the cognitive dimension/domain in major depressive disorder.Drugs, games, and devices for enhancing cognition: implications for work and society.Mood Therapeutics: Novel Pharmacological Approaches for Treating DepressionEffects of erythropoietin on memory-relevant neurocircuitry activity and recall in mood disorders.Is erythropoietin a worthy candidate for traumatic brain injury or are we heading the wrong way?Erythropoietin prevents the effect of chronic restraint stress on the number of hippocampal CA3c dendritic terminals-relation to expression of genes involved in synaptic plasticity, angiogenesis, inflammation, and oxidative stress in male rats.Could EPO studies improve mood disorder treatment strategies?Maintained superiority of chronotherapeutics vs. exercise in a 20-week randomized follow-up trial in major depression.Neural correlates of improved executive function following erythropoietin treatment in mood disorders.High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial.Erythropoietin as an add-on treatment for cognitive side effects of electroconvulsive therapy: a study protocol for a randomized controlled trial.Carbamoylated erythropoietin modulates cognitive outcomes of social defeat and differentially regulates gene expression in the dorsal and ventral hippocampus.GSK3β: a plausible mechanism of cognitive and hippocampal changes induced by erythropoietin treatment in mood disorders?
P2860
Q26750850-258494A0-8C39-41AD-AFA8-29E67B121FBDQ26775386-D9F62304-3A47-42EF-AD7C-2A99DFD90DE1Q26782993-DB2E167D-D676-4A90-96C9-EA3BEA525A7CQ30374324-D01322B0-2B15-490F-BFDC-BE934D388EF2Q35642010-105A34AE-0EBF-40BA-AC5D-9EB836CDBE21Q37724782-9E557741-2CEF-4832-8947-99A1D169DF01Q38255341-9A2AA6D9-E9BF-4405-ACF4-163667A5EEFCQ38543238-AAA47415-3FC2-42CD-B973-19DF00DAE042Q38569937-50F02E62-D3D9-4B6F-8657-FCE0A4588021Q38797653-2A36EBC4-6045-49CA-BE19-779C5A40F118Q38990885-3DD5AF38-2692-4F0F-B97C-DD33D2C59ED1Q39711804-4D677931-6D4A-4ED3-A8C6-3DEB263AA391Q42762679-CA519A0E-8192-4525-86A2-BF8DD64E9210Q47813569-13E4F9E6-B517-4AA7-B5D9-8CACD99B178AQ47852885-0D505580-7189-44B9-B702-640EA95911A3Q47993597-66C6DF22-6321-4A54-83E5-AAA649325325Q48060571-C3023563-44A5-4996-BD0F-C0E0394A648CQ48592362-54ECE202-C3A6-42E8-B6B2-A6F8209552BDQ55262379-A77BC306-8DAC-457D-9F57-18B414E14B6BQ55477135-54D92D19-A7A5-4B03-B61C-534E1933F033Q57477426-A98EDF25-39B9-491D-944E-3BF83162DFA2
P2860
Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Recombinant human erythropoiet ...... cebo-controlled phase 2 trial.
@en
Recombinant human erythropoiet ...... cebo-controlled phase 2 trial.
@nl
type
label
Recombinant human erythropoiet ...... cebo-controlled phase 2 trial.
@en
Recombinant human erythropoiet ...... cebo-controlled phase 2 trial.
@nl
prefLabel
Recombinant human erythropoiet ...... cebo-controlled phase 2 trial.
@en
Recombinant human erythropoiet ...... cebo-controlled phase 2 trial.
@nl
P2860
P50
P921
P356
P1476
Recombinant human erythropoiet ...... cebo-controlled phase 2 trial.
@en
P2093
Ellen M Christensen
Jens D Bukh
P2860
P2888
P304
P356
10.1038/NPP.2013.335
P407
P577
2013-12-10T00:00:00Z